Benzinga | Feb 18, 2021 06:12AM EST

Needham Maintains Buy on Globus Medical, Raises Price Target to $75

Needham analyst Mike Matson maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $65 to $75.